Reports

Pivotal clinical trials for etanercept biosimilars

Home/Reports | Posted 04/09/2015

Biosimilars of Amgen/Pfizer’s blockbuster arthritis drug Enbrel (etanercept), a fusion protein produced by recombinant DNA, are currently under development.

Biosimilar events from 2013 to 2015

Home/Reports | Posted 19/06/2015

During the period of 2013 to 2015, biosimilars has been increasingly on the agenda around the world. Biosimilars are making steady progress, as can be seen by the increasing number of events, including approvals for biosimilars around the world [1].

Payers in US getting ready for biosimilars

Home/Reports | Posted 22/04/2016

Payers in the US are getting ready for the advent of biosimilars, according to a report published by biotech giant Amgen.

Payers in US view biosimilars as a lower-cost branded option

Home/Reports | Posted 15/04/2016

Payers in the US do not expect the biosimilars market to be like the generics market and they also do not expect the US biosimilars market to be like that in Europe, according to a report published by biotech giant Amgen.

Impact of antidepressant generics in Europe

Home/Reports | Posted 08/04/2016

Use of generic antidepressants may improve adherence and reduce the cost of pharmacotherapy for depression in European countries, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).

Impact of breast cancer generics in Europe

Home/Reports | Posted 25/03/2016

Breast cancer generics can increase patient adherence and reduce healthcare budgets for European countries, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).

Impact of hypertension generics in Europe

Home/Reports | Posted 04/03/2016

A report by the Germany-based Institute for Healthcare and Social Research (IGES) released in November 2015 found that generics of drugs to treat high blood pressure can increase patient adherence and reduce healthcare budgets for European countries.

Impact of generics on European budgets

Home/Reports | Posted 12/02/2016

A report by the Germany-based Institute for Healthcare and Social Research (IGES) released on 16 November 2015 found that generics could contribute to reducing healthcare budgets for European countries.

Generics market share in Europe

Home/Reports | Posted 22/01/2016

Generics make a major contribution to the European drug supply, according to a report by the by Germany-based Institute for Healthcare and Social Research (IGES).

Generics reduce costs and increase access

Home/Reports | Posted 08/01/2016

Generics reduce costs for both patients and payers and increase patient’s access to medicines, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).

Generics savings continue to climb in the US

Home/Reports | Posted 04/12/2015

Generics manufacturers have joined to celebrate the latest data from the Generic Drug Savings in the US report. According to the report, the US healthcare system saved a record US$254 billion in 2014 from generics, or US$1.68 trillion between 2005 and 2014.

Pivotal clinical trials for trastuzumab biosimilars

Home/Reports | Posted 06/11/2015

Biosimilars of Roche’s Herceptin (trastuzumab), a humanized monoclonal antibody are currently under development.

Pivotal clinical trials for rituximab biosimilars

Home/Reports | Posted 30/10/2015

Biosimilars of Roche’s MabThera/Rituxan (rituximab), a chimeric monoclonal antibody are currently under development.

German physicians not pressured to switch to biosimilar infliximab

Home/Reports | Posted 02/10/2015

Rheumatologists and gastroenterologists in Germany are not being put under pressure to switch patients from Remicade (infliximab) to biosimilar infliximab, according to a new report from research and advisory firm Decision Resources.

Pivotal clinical trials for bevacizumab biosimilars

Home/Reports | Posted 18/09/2015

Biosimilars of Roche’s Avastin (bevacizumab), a humanized monoclonal antibody, are currently under development.

Generics use in Italy could save Euros 1.4 billion per year

Home/Reports | Posted 05/06/2015

A report published by Italian generics association Assogenericion on 5 May 2015 points to the fact that generics are crucial in the containment of pharmaceutical expenditure in Italy.

Clinical programmes for oncology biosimilars

Home/Reports | Posted 28/08/2015

Biosimilars for oncology drugs are currently under development. These include biosimilars of blockbusters such as Roche’s Avastin (bevacizumab), MabThera/Rituxan (rituximab) and Herceptin (trastuzumab).

Doctors’ survey reveals lack of confidence in biosimilars

Home/Reports | Posted 21/08/2015

Online physician’s platform and community QuantiaMD survey of 300 primary care physicians and specialists in the US has found a lack of confidence concerning biosimilars.

Clinical programmes for anti-TNF biosimilars

Home/Reports | Posted 14/08/2015

Biosimilars for anti-tumour necrosis factor (anti-TNF) drugs are currently under development. These include biosimilars of blockbusters such as AbbVie’s Humira (adalimumab), Amgen’s Enbrel (etanercept) and Johnson & Johnson’s Remicade (infliximab).

Cost reductions due to biosimilars in Europe

Home/Reports | Posted 07/08/2015

Biosimilars have been approved in the European Union since 2006 in the classes of erythropoietin (EPO), human growth hormone (HGH), granulocyte colony-stimulating factor (G-CSF) and anti-tumour necrosis factor (anti-TNF). Despite the fact that they have been in use since 2006, the prices for EPO, HGH and G-CSF classes of drugs in some countries have not reduced by as much as some might have expected. There is also a significant variation between different countries in Europe [1].

Generics and biosimilars Initiative

News

Research

General